Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection.
Yang H, Chen Y, Jiang D, Feng X, Xu Y, Wei J, Zou Q, Yang Q, Chen J, Jiang X, Qin C, Huang Z, Wu C, Zhou Y, Li M, Yin L.
Yang H, et al. Among authors: yang q.
Antib Ther. 2023 Mar 6;6(2):97-107. doi: 10.1093/abt/tbad003. eCollection 2023 Apr.
Antib Ther. 2023.
PMID: 37077474
Free PMC article.